You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,309,532

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,309,532

Title:	Therapeutic uses of inhibitors of RTP801
Abstract:	The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
Inventor(s):	Feinstein; Elena (Rehovot, IL), Kaufmann; Jorg (Berlin, DE), Giese; Klaus (Berlin, DE)
Assignee:	Quark Pharmaceuticals, Inc. (Fremont, CA)
Application Number:	12/803,118
Patent Claims:	1. A method of treating a subject suffering from an eye disease which comprises administering to the subject an RTP801 inhibitor and a VEGF inhibitor, so as to thereby treat the subject, wherein the RTP801 inhibitor is an antisense compound or an siRNA compound which inhibits expression of the RTP801 gene. 2. The method of claim 1, wherein the RTP801 inhibitor is an siRNA compound which inhibits RTP801 expression. 3. The method of claim 2, wherein the RTP801 siRNA compound comprises an antisense strand, the sequence of which comprises a sequence selected from the group consisting of: TABLE-US-00007 5'AGCUGCAUCAGGUUGGCAC (SEQ ID NO: 66); 5'UUCUAGAUGGAAGACCCAG (SEQ ID NO: 74); 5'UUGAACAUCAAGUGUAUUC (SEQ ID NO: 75); 5'AAAAAUAUUGCAUAGGUCU (SEQ ID NO: 77); 5'UACUUGAACAUCAAGUGUA (SEQ ID NO: 79); and 5'AACUCAAUGAGCUUCCUGG (SEQ ID NO: 91). 4. The method of claim 3, wherein the sequence is TABLE-US-00008 5'AGCUGCAUCAGGUUGGCAC (SEQ ID NO: 66). 5. The method of claim 1, wherein the VEGF inhibitor is an anti-VEGF antibody. 6. The method of claim 5, wherein the anti-VEGF antibody is Ranibizumab. 7. The method of claim 1, wherein the administering comprises intravitreal injection. 8. The method of claim 1, wherein the eye disease is selected from the group consisting of choroidal neovascularization (CNV), wet AMD, dry AMD, glaucoma, diabetic retinopathy, diabetic macular edema, ocular histoplasmosis syndrome, angioid streaks, ruptures in Bruch's membrane, myopic degeneration, ocular tumors, retinal degenerative disease, and retinal vein occlusion (RVO). 9. The method of claim 8, wherein the eye disease is diabetic macular edema.

Details for Patent 8,309,532

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2024-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2024-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2024-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2024-08-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.